Dr Aaron O’Sullivan completed his undergraduate degree in Industrial Biochemistry at the University of Limerick (UL) before pursuing a PhD at UL under the supervision of Associate Professor Luis Padrela and Professor Kevin Ryan at the Bernal Institute.
Aaron’s research focused on the development and understanding of pharmaceutical cocrystals using atomization-based technologies – particularly Supercritical Enhanced Atomization (SEA) – as a route to address API challenges such as poor bioavailability and aqueous solubility. His PhD contributed new formulations, methodologies, and scalable solutions to a wide array of pharmaceutical cocrystals using supercritical fluid-based processing, helping to bridge the gap between academic innovation and industrial translation.
Today, Aaron applies his expertise as a Scientist TS/MS at Eli Lilly, continuing to make an impact in pharmaceutical science.
“I have had the privilege of mentoring Aaron throughout his research journey, where his exceptional contributions to the field of supercritical fluid (SCF) technology have truly set him apart. His willingness and energy to work hard during his PhD have boosted his research outputs and advancements in his field. His groundbreaking work on the control of solid-state and particle size in pharmaceutical cocrystals using supercritical fluids exemplifies the qualities of creativity, innovation, and scientific excellence.” Professor Luis Padrela
One of Aaron’s most notable achievements was the discovery of a new cocrystalline form of Celecoxib, synthesized using supercritical fluid methods. This innovation doubled the drug’s dissolution rate, addressing a critical challenge in poorly soluble drug formulations. His ability to characterize this novel cocrystal and analyse its thermal properties underscores his deep expertise in material science.
Beyond cocrystals, Aaron advanced nanoparticle technology through the development of the Multi-Nozzle Supercritical Enhanced Nano Coating (MUSENC) method. This breakthrough improves nanoparticle production efficiency and scalability, tackling long-standing issues such as particle aggregation and poor flowability—transforming pharmaceutical manufacturing potential.
Aaron’s impact extends beyond the lab. He has been recognized as a thought leader in supercritical fluid research, delivering a keynote address at EMSF2023 and publishing multiple first-author papers in leading scientific journals.
Congratulations to Dr Aaron O’Sullivan on this well-deserved recognition as SSPC Graduate of the Year. His innovation and dedication continue to push the boundaries of pharmaceutical science.
